4d Molecular Therapeutics, Inc. · NASDAQ:FDMT
4d Molecular Therapeutics — Technical Presentation (January 2025)
16 slides from 4d Molecular Therapeutics's technical presentation, Jan 10, 2025
Slide 1: Intravitreal 4D-150 DME Clinical Trial: Part 1 Interim 32-week Results
Intravitreal 4D-150 DME Clinical Trial: Part 1 Interim 32-week Results January 10, 2025 EXHIBIT 99.1
Slide 2: Legal Disclaimer
Legal Disclaimer This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Presentation, including statements regarding our clinical development plans, strategy, future operatio
Slide 3: Positive Interim Data & FDA Feedback Supports Advancement of 4D-150 to Phase 3 in DME
4D-150 continues to be well tolerated: No intraocular inflammation observed at any timepoint or dose level All patients completed the 16-week topical steroid taper on schedule and remained completely off steroids No hypotony, endophthalmitis, vasculitis, choroidal effusions or retinal artery occlusi
Slide 4: Part 1: Designed to Enroll Patients with High CST and Stringent Supplemental Criteria
Part 1: Designed to Enroll Patients with High CST and Employed Stringent Supplemental Criteria, with Focus on Safety & Dose Selection *Assessed by SD-OCT and confirmed by independent reading center. †Safety and tolerability (frequency and severity of treatment emergent adverse events). CST, central
Slide 5: SPECTRA Disease Activity Criteria for Supplemental Treatment Are Stringent Compared to Other Trials
SPECTRA Disease Activity Criteria for Supplemental Treatment Are Stringent Compared to Other Trials and Did Not Require Vision Decrease *After Week 24. †After Week 12. ‡After Week 8. BCVA, best corrected visual acuity; CST, central subfield thickness; ETDRS, Early Treatment Diabetic Retinopathy Stud
Slide 6: Study Population: Baseline CST, BCVA, and Prior Treatment Status Balanced Across Dose Arms
Study Population: Baseline CST, BCVA, and Prior Treatment Status Balanced Across Dose Arms BCVA, best corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study. 1 patient in 1E10 vg/eye arm terminated the study due to death unrelated to 4D-150 prior to completion of a post-baseline
Slide 7: SPECTRA Designed With Fewer Loading Doses and High CST Population
SPECTRA Designed With Fewer Loading Doses and Enrolled Population With High CST and Majority Treatment Experienced CST, central subfield thickness; BCVA, best corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study. Sources: 1. Korobelnik et al. Ophthalmology 2014;121:2247–54. 2.
Slide 8: 4D-150 Continues to be Well Tolerated
4D-150 Continues to be Well Tolerated Data cutoff date, December 13, 2024. 4D-150 continues to be well tolerated with no intraocular inflammation at any timepoint at any dose level All patients completed the 16-week topical steroid taper on schedule and remained completely off steroids No hypotony,
Slide 9: No Intraocular Inflammation and All Patients Completed Prophylactic Topical Steroids on Schedule
No Intraocular Inflammation and All Patients Completed Prophylactic Topical Steroids on Schedule and Remained Completely Off Steroids Data cutoff date, December 13, 2024. *Excludes patient with early termination due to death (unrelated to 4D-150) prior to completion of a post-baseline assessment. NE
Slide 10: 4D-150 3E10 vg/eye: Sustained Improvement in Visual Acuity Through 32 Weeks
4D-150 3E10 vg/eye: Sustained Improvement in Visual Acuity Through 32 Weeks (+8.4 Letters vs Baseline) Week Supplemental Injections**, n 3E10 vg/eye (n=9) 0 0 2 0 2 1 0 0.6 1E10 vg/eye (n=11) 1 2 2 4 2 1 3 1.4 +8.4 +7.1 Aflibercept Mean per patient Data cutoff date, December 13, 2024. *Excludes pati
Slide 11: On-label Eylea Improves CST ~165 µm But Requires High Treatment Burden
Eylea Phase 3 Studies in DME1 Compared 5 Loading Doses + Q4W or Q8W vs. Laser On-label Eylea Improves CST ~165 µm But Requires High Treatment Burden 1. Korobelnik et al. Ophthalmology 2014;121:2247–54. Aflibercept 2mg 5 Load + Q8W Eylea consistently achieved CST improvements of ~165 µm in DME patien
Slide 12: 4D-150 3E10 vg/eye: Sustained Improvement in Anatomic Control Through 32 Weeks
4D-150 3E10 vg/eye: Sustained Improvement in Anatomic Control Through 32 Weeks (–194 µm vs Baseline) -194 -153 Data cutoff date, December 13, 2024. *Excludes patient with early termination due to death (unrelated to 4D-150) prior to completion of a post-baseline assessment. **No patient in 3E10 or 1
Slide 13: 3E10 vg/eye Post-loading Phase: 86% Reduction in Treatment Burden vs. Aflibercept
3E10 vg/eye Post-loading Phase: 86% Reduction in Treatment Burden vs. Projected On-label Aflibercept 2mg Q8W; Dose Response in Favor of 3E10 Data cutoff date, December 13, 2024. *Excludes patient with early termination due to death (unrelated to 4D-150) prior to completion of a post-baseline assessm
Slide 14: Positive Interim Data & FDA Feedback Supports Advancement of 4D-150 to Phase 3 in DME
4D-150 continues to be well tolerated: No intraocular inflammation observed at any timepoint or dose level All patients completed the 16-week topical steroid taper on schedule and remained completely off steroids No hypotony, endophthalmitis, vasculitis, choroidal effusions or retinal artery occlusi
Slide 15: Thank You
THANK YOU 5858 Horton Street, Suite 455 | Emeryville, California 94608 (510) 505-2680 | Investor.Relations@4DMT.com IR.4DMT.com | LinkedIn
Slide 16: On-label Aflibercept Improves CST by ~150-180 µm with Rebound Observed at Week 24
On-label Aflibercept Improves CST by ~150-180 µm with 7 Total Injections Through 40 Weeks; Rebound Observed at Week 24 Despite 5 Loading Doses 1. Korobelnik et al. Ophthalmology 2014;121:2247–54. 2. Brown et al. Lancet 2024;403:1153–63. 3. Wykoff et al. Lancet 2022;399:741–55. PHOTON2 Aflibercept 2m
4D Molecular Therapeutics — Technical Presentation (January 2025) on 6ix